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Abstract
In this paper, a positive state observer is designed for the implementation of
a control law proposed for the automatic administration of propofol and of
remifentanil in order to track a desired level for the bispectral index (BIS).
The BIS is used as a measure of the depth of anesthesia. It is proved and
illustrated by simulations that the controller-observer scheme has a very good
performance. This control scheme was implemented, tested and evaluated in
real patients during surgical procedures. A set of clinical results are here
presented.
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1. Introduction
General anesthesia enables a patient to tolerate surgical procedures that
would otherwise inflict unbearable pain, potentiate extreme physiologic ex-
acerbations, and result in unpleasant memories. The components of general
anesthesia are areflexia (paralysis), hypnosis (unconsciousness and amnesia),
and analgesia (absence of any sensation, including pain). The depth of anes-
thesia (DoA) is related to the intensity of these two latter components and
is achieved by the administration of two drugs: a hypnotic and an anal-
gesic. According to several studies (Tirén et al. [1], Grindsta  and Tobias
[2], Ekman et al. [3], Wodey et al. [4], Whyte and Booker [5]) the DoA may
be measured by means of the bispectral index (BIS). This index is a single
dimensionless number, which is computed from the electroencephalogram
(EEG) and ranges from 0 (equivalent to EEG silence) to 100 (equivalent to a
fully awake and alert state). A BIS value between 40 and 60 is clinically de-
sirable for general anesthesia purposes. This is usually achieved manually by
the anesthesiologists. However, due to the high complexity of this procedure
an automated system for drug administration would be a good support for
the clinicians (see Meijler [6]). The development of controllers for the auto-
matic administration of drugs in patients has deserved the attention of several
researchers and led to a number of contributions and controllers namely a
predictive control in Ionescu et al. [7], an adaptive model-based controller in
Mortier et al. [8] and Simanski et al. [9], a PID in Padula et al. [10], a neural
in Ortolani et al. [11], a fuzzy logic in Shieh et al. [12], a model predictive
control in Sawaguchi et al. [13] and Chang et al. [14], but in these contri-
butions the control of the DoA is not fully automatic. More concretely, the
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administration of the hypnotic is made automatically, but the administration
of the analgesic is manually made by a clinician. A detailed introduction to
anesthesia as a control problem together with a good overview of the state
of the art can be found in Lemos et al. [15] and Chang et al. [16].
In Nogueira et al. [17] a control law was proposed for the BIS tracking of pa-
tients, during general anesthesia, by means of the automatic administration
of both the hypnotic (propofol) and the analgesic (remifentanil). Moreover,
this controller has the advantage of allowing di erent combinations of the
two drugs in order to obtain the same value for the BIS level, and allows
the changing of the desired reference value for the BIS during the surgical
procedure. However the corresponding control law makes use of the state of
the patient, which is not completely available for measurement. Therefore
the controller cannot be directly implemented in the operation room. To
overcome this drawback, in this paper, we introduce a state observer in or-
der to estimate the state of the patient model based on the measurements of
the BIS response and the amounts of administered drugs. This observer, to-
gether with the controller proposed in [17], was used in clinical environment
under the supervision of an anesthetist, and the corresponding results are
presented here. These results encourage the use of the proposed controller-
observer scheme for the control of the depth of anesthesia.
The structure of this paper is as follows. Section 2 is devoted to the ex-
planation of the BIS model, while the control law is presented in Section
3. In Section 4 a positive state observer is proposed and its performance is
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illustrated in Section 5. Clinical case are presented in Section 6. Conclusions
are drawn in Section 7.
2. Model description
The patient BIS level obtained by means of the administration of the hypnotic
propofol and of the analgesic remifentanil may be modeled by a new Wiener
model recently introduced in the literature Silva et al. [18] and known as the
parameter parsimonious model (PPM). According to this model, the linear
relations between the propofol and remifentanil dosages and the correspond-
ing e ect concentrations (cp
e
and cr
e
) are modeled by the transfer functions:
Hp(s) = k1k2k3–
3
(k1– + s)(k2– + s)(k3– + s)
up(s), (1)
Hr(s) = l1l2l3÷
3
(l1÷ + s)(l2÷ + s)(l3÷ + s)
ur(s), (2)
respectively, where – and ÷ are patient dependent parameters, without any
explicit physiological meaning, k1, k2, k3 and l1, l2, l3 are adimensional con-
stants whose values were identified in Silva et al. [18] from a real patient
database, as: k1 = 10, k2 = 9, k3 = 1, l1 = 3, l2 = 2, l3 = 1. The complex
functions up(s) and ur(s) are the Laplace transforms of the administered
doses of propofol, up(t), and of remifentanil, ur(t), in mg min≠1. The corre-
sponding BIS level, z(t), usually given by the generalized Hill equation Minto
et al. [19], is approximated in Silva et al. [18] by the nonlinear equation:
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z(t) = 97.71 + U“ , (3)
where U = µ c
p
e
ECp50
+ c
r
e
ECr50
, and µ and “ are patient dependent parameters,
without any physiological meaning, 97.7 is the BIS level at zero concentra-
tion, and ECp50 and ECr50 respectively denote the propofol and remifentanil
concentrations that produce half the maximal e ect when the drug acts in
isolation. The parameters ECp50 and ECr50 are taken to be fixed, namely
ECp50 = 10 mg/ml and ECr50 = 0.01 mg/ml. These values were obtained in
the work developed in Mendonça et al. [20].
The PPM may be also represented by the following state space represen-
tation:
Y
_______________________]
_______________________[
ẋ(t) = Ax(t) + Bu(t)
S
WU
cp
e
(t)
cr
e
(t)
T
XV =
S
WU
0 0 1 0 0 0
0 0 0 0 0 1
T
XV x(t)
U(t) = Cx(t)
z(t) = 97.71 + U“ ,
(4)
where
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C =
5
0 0 0.1µ 0 0 100
6
,
A =
S
WU
Ap 0
0 Ar
T
XV , B =
S
WU
Bp 0
0 Br
T
XV ,
Ap =
S
WWWWWU
≠10– 0 0
9– ≠9– 0
0 – ≠–
T
XXXXXV
, Ar =
S
WWWWWU
≠3÷ 0 0
2÷ ≠2÷ 0
0 ÷ ≠÷
T
XXXXXV
,
Bp =
S
WWWWWU
10–
0
0
T
XXXXXV
, Br =
S
WWWWWU
3÷
0
0
T
XXXXXV
.
(5)
This state space model is more suited to model based control, since it has a
reduced number of parameters to be identified. However, contrary to what
happens with PK/PD models, most of the state components lack a phys-
iological meaning. Nevertheless, model (4)-(5) exhibits a compartmental
structure, which has the advantage of allowing the use of the positive control
law defined in the next section.
3. Controller description
The nonlinear controller presented in Nogueira et al. [17] was designed for the
automatic administration of propofol and of remifentanil in order to control
the BIS level of a patient. This control law, which results from a combination
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of a linear controller with a positivity constraint for the drug doses, is defined
by:
u(t) =
S
WU
up(t)
ur(t)
T
XV =
S
WU
max(0, ũp(t))
max(0, ũr(t))
T
XV , (6)
where up is the input of propofol and ur is the input of remifentanil, with:
ũ(t) =
S
WU
ũp(t)
ũr(t)
T
XV = E (≠KAx(t) + ⁄(Mú ≠ Kx(t))) , (7)
and
E =
S
WU
fl1
fl2
T
XV
1
–fl1 + 300÷fl2
, (8)
Mú = 3(0.1fl1 + 100fl2)0.1µfl1 + 100fl2
397.7
zú
≠ 1
4 1
“
, (9)
K =
5
0.1 0.1 0.1 100 100 100
6
, (10)
with (fl1 Ø 0 and fl2 = 1) or (fl1 = 1 and fl2 Ø 0). In (9), zú is the desired BIS
level, and ⁄, fl1 and fl2 are positive design parameters. The parameter ⁄ does
not a ect the achieve steady state value but does influence the convergence
speed to the desired reference value. The parameters fl1 and fl2 do not a ect
the tracking performance. When fl1 = 1 the parameter fl2 can be interpreted
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as the proportion between the doses of remifentanil and propofol, and when
fl2 = 1 the parameter fl1 can be interpreted as the proportion between the
doses of propofol and remifentanil. This allows choosing fl1 and fl2 according
to clinical criteria. In fact, this type of reasoning can be also followed for the
simultaneous administration of any other two drugs.
In the particular case of the administration of propofol and remifentanil to
induce depth of anesthesia, it is more convenient to consider fl1 = 1 and to
define fl := fl2 Ø 0; this corresponds to the case where the dose of propofol is
not constantly zero, which is more in accordance with clinical practice. The
case fl2 = 1 and fl := fl1 Ø 0 can be dealt with in a completely analogous way.
For more details about this controller and its tracking properties, the reader
is referred to Nogueira et al. [17].
4. State Observer
To control the DoA of a patient in the previous section, we assumed that all
the state components of the model could be measured. However this does not
happen in practice. In order to overcome this handicap, here, an observer  
is designed to estimate the states of the PPM, by observing the BIS of a real
patient and the administered doses of propofol and remifentanil.
Consider the PPM, as described in (4)
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Y
_____]
_____[
ẋ(t) = Ax(t) + Bu(t)
U(t) = Cx(t) =
5
0 0 0.1µ 0 0 100
6
x
z(t) = z01+U“ ,
(11)
The observability matrix of the PPM has rank 6; therefore the state x is
completely observable from the input u and the output U(t). This allows to
design an observer with gain L for the state of this model. However, instead
of using the output U(t) of the model, we estimate the state from the real
BIS response of a patient, from which a value of the real combined drug
potency, U
patient
(t), can be computed by inversion of the Hill equation. Due
to model misfit and to the presence of noise in the measurement of the BIS
level, the values of U
patient
(t) and U(t) do not coincide. Letting
Á(t) = U
patient
(t) ≠ U(t) (12)
the PPM state observer based on the measurement of the patient BIS level
is described by the following equations:
Y
________]
________[
ẋ(t) = Ax(t) + Bu(t)
U(t) = Cx(t)
U
patient
(t) = Cx(t) + Á(t)
˙̃x(t) = (A ≠ LC)x̃(t) + Bu(t) + LU
patient
(t),
(13)
where x̃ is the (not necessarily positive) estimate of the state.
Denoting the estimation error by e = (x ≠ x̃) one has that:
ė(t) = (A ≠ LC)e(t) ≠ LÁ(t). (14)
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Moreover, e(0) = 0, because when the process starts the state x(0) of the
PPM is zero (as no drugs were administered) and the initial condition x̃(0)
for the state estimate is set to zero.
Due to the stability of A ≠ LC, if |Á(t)| is bounded, so is ||e(t)||. If the
patient is well modeled by the PPM we may assume that this is the case,
i.e., |Á(t)| < Á̄, for some small value Á̄, which implies that ||e(t)|| Æ ē, with
ē = ÎgÎ1Á̄, g(·) = e(A≠LC)· L, and ÎgÎ1 :=
s Œ
0 g(·)d· .
Now, since the state of the PPM is always positive, instead of taking the
estimate x̃, the positive estimate x̂(t) = max{0, x̃(t)} is considered, where
the maximum is taken componentwise. Note that Îx ≠ x̂Î Æ Îx ≠ x̃Î Æ ē,
because Îx ≠ x̂Î =
Òq6
i=1(xi ≠ x̂i)2 and xi≠x̂i Æ xi≠x̃i, since, if x̃i < 0 then
x̂
i
= 0 and x
i
≠ x̂
i
= x
i
< x
i
≠ x̃
i
. If x̃
i
Ø 0 then x̂
i
= x̃
i
and x
i
≠ x̂
i
= x
i
≠ x̃
i
.
When instead of the state x the estimate x̂ is used in the control law (7), a
control input û(t) is obtained, which is described by the following expressions:
û(t) = max(0, ˆ̃u(t)), (15)
with
ˆ̃u(t) = ũ(t) +
S
WU
1
fl
T
XV (KAe(t) + ⁄Ke(t))
1
– + 300÷fl , (16)
= ũ(t) + ū(t),
where ⁄ > 0 and
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ū(t) =
S
WU
1
fl
T
XV (KAe(t) + ⁄Ke(t))
1
– + 300÷fl (17)
= Re(t), (18)
with R =
S
WU
1
fl
T
XV
1
– + 300÷flK (A + ⁄In).
As will be proved next, the error  u(t) = u(t) ≠ û(t) in the computed drug
doses is bounded. For this purpose we consider four di erent cases separately.
Case one - Both ũ(t) and ˆ̃u(t) are negative
When ũ(t) and ˆ̃u(t) are both negative, u(t) = û(t) = 0, then  u(t) = 0,
which means that û(t) presents no errors.
Case two - Both ũ(t) and ˆ̃u(t) are positive
When ũ(t) and ˆ̃u(t) are both positive, the error  u(t) is given by:
 u(t) = ≠Re(t), (19)
and Î u(t)Î is bounded by:
Î u(t)Î Æ Î≠RÎ Îe(t)Î (20)
Æ ÎRÎ ē, (21)
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where the notation v < w, for two vectors v =
S
WWWWWU
v1
...
v
j
T
XXXXXV
and w =
S
WWWWWU
w1
...
w
j
T
XXXXXV
,
means that v
i
< w
i
, for i = 1 · · · j.
Case three - ũ(t) < 0 and ˆ̃u(t) > 0
In this case u(t) = 0 and û(t) = ˆ̃u(t) > 0.
Since ˆ̃u(t) = ũ(t) + ū(t), one has that
0 < ˆ̃u
j
(t) = ũ
j
(t) + ū
j
(t) < ū
j
(t), j = 1, 2. (22)
Thus,
Î u(t)Î = Îu(t) ≠ û(t)Î (23)
=
...0 ≠ ˆ̃u(t)
... (24)
=
...ˆ̃u(t)
... (25)
=
ı̂ıÙ
2ÿ
j=1
(ˆ̃u
j
(t))2 (26)
<
ı̂ıÙ
2ÿ
j=1
(ū
j
(t))2 (27)
= Îū(t)Î (28)
= ÎRe(t)Î (29)
Æ ÎRÎ ē. (30)
Case four - ũ(t) > 0 and ˆ̃u(t) < 0
12
In this case u(t) = ũ(t), û(t) = 0, and  u(t) = ũ(t).
Since ˆ̃u(t) = ũ(t) + ū(t) < 0, one has that
0 < ũ
j
< ≠ū
j
, j = 1, 2, (31)
and hence
Î u(t)Î = Îũ(t)Î (32)
=
ı̂ıÙ
2ÿ
j=1
(ũ
j
(t))2 (33)
<
ı̂ıÙ
2ÿ
j=1
(≠ū
j
(t))2 (34)
= Îū(t)Î (35)
Æ ÎRÎ ē. (36)
This proves that the norm of the error, Î uÎ, of the computed drug doses
to be administered is bounded by ū
ē
:= ÎRÎ ÎgÎ1Á̄. The e ect that this error
produces in the controlled BIS of a patient is analyzed next.
In a first step, the influence of the input error  u on the model BIS is
studied. Recalling the first two equations of (13), the model response Û(t)
to the input û(t) = u(t) ≠  u(t) is given by:
Û(t) = CeAtx(0) +
⁄
t
0
CeA· Bû(t ≠ ·)d·, (37)
whereas the model response U(t) to the input u(t) is given by:
U(t) = CeAtx(0) +
⁄
t
0
CeA· Bu(t ≠ ·)d·. (38)
Thus, the error  U(t) = U(t) ≠ Û(t) is:
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 U(t) =
⁄
t
0
CeA· B(u(t ≠ ·) ≠ û(t ≠ ·))d· (39)
=
⁄
t
0
CeA· B u(t ≠ ·)d·. (40)
Consequently, since Î u(t ≠ ·)Î < ÎRÎ ē = ÎRÎ ÎgÎ1Á̄,
| U(t)| Æ ÎhÎ1 ÎRÎ ÎgÎ1Á̄, (41)
with h(·) = CeA· B, i.e.,
|U(t) ≠ Û(t)| Æ »Á̄, (42)
for » = ÎhÎ1 ÎRÎ ÎgÎ1.
Since lim
tæŒ U(t) = Uú, for su ciently large t, we may assume that |Uú ≠
Û(t)| Æ »Á̄.
As Û(t) = Û
patient
(t) ≠ Á(t), where Û
patient
(t) is the patient combined drug
potency response corresponding to the administration of the dose û(t), one
concludes that
|Uú ≠ Û
patient
(t) + Á(t)| Æ »Á̄, (43)
i.e.,
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Uú + Á(t) ≠ »Á̄ Æ Û
patient
Æ Uú + Á(t) + »Á̄ (44)
Uú ≠ |Á(t)| ≠ »Á̄ Æ Û
patient
Æ Uú + |Á(t)| + »Á̄ (45)
Uú ≠ Á̄ ≠ »Á̄ Æ Û
patient
Æ Uú + Á̄ + »Á̄ (46)
Uú ≠ (1 + »)Á̄ Æ Û
patient
Æ Uú + (1 + »)Á̄. (47)
Since the patient BIS response to Û
patient
, ẑ
patient
, is a decreasing function of
Û
patient
, one has that
f(Uú + (1 + »)Á̄) Æ ẑ
patient
Æ f(Uú ≠ (1 + »)Á̄), (48)
with
f(U) = z01 + U“ . (49)
Since
f(Uú +  ) ƒ f(Uú) + df
dU
|
U=Uú  (50)
= zú + df
dU
|
U=Uú , (51)
(48) implies that
zú ≠ “z0(U
ú)“≠1
(1 + (Uú)“)2 (1+»)Á̄ Æ ẑpatient Æ z
ú + “z0(U
ú)“≠1
(1 + (Uú)“)2 (1+»)Á̄. (52)
This means that when our proposed control law is combined with a state
observer based on the BIS patient measurements, the patient BIS level con-
verges to the interval
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I =
D
zú ≠ “z0(U
ú)“≠1
(1 + (Uú)“)2 (1 + »)Á̄ , z
ú + “z0(U
ú)“≠1
(1 + (Uú)“)2 (1 + »)Á̄
C
. (53)
As expected, the desired steady state value zú is not achieved, but the patient
BIS remains in a neighborhood of this target value, whose radius decreases
with Á̄. Thus, if the modeling error and measurement noise are su ciently
small, the patient achieved BIS level is close to zú.
5. Observer Performance
Here, the performance of the DoA control of a simulated patient using an ob-
server in order to estimate the state of the corresponding model, as previously
explained (see equation (13)), is illustrated by simulations. For this purpose,
the control law is applied to a simulated patient that was set up based on
the data of a real patient (Patient 13 of the database presented in Appendix
B), a woman, with 68 years of age, a height of 158 cm, and 113 Kg who was
subject to general anesthesia under propofol and remifentanil administration
during a breast surgery. The DoA was monitored by the BIS and was man-
ually controlled around clinically accepted values by the anesthetist. Alaris
GH pumps were used to administer both drugs, propofol and remifentanil.
Infusion rates, BIS values and other physiological variables were acquired
every five seconds ([20]).
For this patient, a PK/PD Wiener model was obtained as follows. The
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linear part was modeled according to [21], [22], and [23] based on the rel-
evant patient characteristics. This corresponding model is summarized in
Appendix A, in equation (A.1). The nonlinear part was taken to coincide
with the generalized Hill equation (3) and the corresponding parameters “
and µ were identified in [20] from the surgery data, being given by: “ = 1.09
and µ = 2.40.
The controller (7) is first tuned assuming that the simulated patient is mod-
eled by the parsimonious parameter Wiener model of [18], with parameters
– = 0.0759, ÷ = 0.5825, “ = 1.09, and µ = 2.40. These values are the
average of the values for –, ÷, “, and µ taken from a bank of identified values
for eighteen real patients obtained in the work developed in [20] (see Table
B.2).
The matrix L of the observer, described in (13), was considered to be:
L =
S
WWWWWWWWWWWWWWWU
≠0.5720
21.1536
≠2.2715
0.0013
≠0.0040
0.0156
T
XXXXXXXXXXXXXXXV
, (54)
so that the eigenvalues of A ≠ LC are approximately 30% faster then the
ones of A. In the following simulations the BIS evolution of the patient is
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illustrated in the presence of Gaussian white noise, with zero mean and stan-
dard deviation ‡
noise
= 3. In order to improve the performance of the control
procedure in the presence of noise, a filter was applied to the noisy BIS signal.
In Figures 1 and 2 the evolution of the DoA of the simulated patient during
120 min is illustrated. In Fig. 1 the desired value for the BIS was set to be
50 during the whole procedure and in Fig. 2 the desired value for the BIS
was set to be 50 from the beginning till t = 50 min, then was set to be 40
from t = 50 min till t = 120 min, and finally was again set to be 50 from
then on. As we can see, in both cases the behavior of the controlled output
of the patient is clinically acceptable.
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Figure 1: Top graph: BIS evolution, in the presence of noise of a simulated patient, using
an observer. The reference value for the BIS level was set to be 50. Bottom graph:
Administered doses of propofol and of remifentanil.
18
0 20 40 60 80 100 120 140 160 180 200
30
40
50
60
70
80
90
100
Time[min]
D
o
A
m
e
a
s
u
r
e
m
e
n
t
(
B
I
S
)
 
 
BIS evolution of the simulated patient
0 20 40 60 80 100 120 140 160 180 200
0
0.1
0.2
0.3
0.4
0.5
Time[min]
I
n
f
u
s
i
o
n
r
a
t
e
(
m
g/
m
in
)
 
 
Infusion of propofol
Infusion of remifentanil
Figure 2: Top graph: BIS evolution, in the presence of noise of a simulated patient, using
an observer and assuming changes in the reference profiles (zú = 50 from the beginning
till t = 50 min, zú = 40 from t = 50 min till t = 120 min, and zú = 50 from then on).
Bottom graph: Administered doses of propofol and of remifentanil.
6. Clinical Cases
The control law (6) was integrated in the Galeno platform ([24]) and was
used for the automatic administration of propofol and remifentanil to real
patients during surgical procedures. This platform was developed in the
framework of the portuguese funding agency (FCT) project Galeno, and in-
corporates several identification and control procedures for automation in
anesthesia. This supervisory automatic drug administration system Galeno
is currently implemented in a surgery room at the ULSM (Pedro Hispano
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Hospital, Matosinhos, Portugal), working under medical surveillance, where
the data here presented were collected. Manual drug administration is ready
to be switched on both under clinical decision or in case of failure of the au-
tomatic controller. The results obtained in the surgery room are presented
in this section.
Patient 1, a man of 86 years of age, 50kg of weight and 1.65m of height
was subject to general anesthesia, for a total gastrectomy. Patient 2, a man
of 85 years of age, 80kg of weight and 1.72m of height was subject to general
anesthesia, for a partial gastrectomy. The DoA was monitored by the BIS
and Alaris GH pumps were used for both propofol and remifentanil. Infu-
sion rates, BIS values and other physiological variables were acquired with
a sampling time of five seconds. The neuromuscular blockade (NMB) was
controlled manually by bolus administration.
The controller (7) was tuned assuming that the patients were modeled by
the parsimonious parameter Wiener model (PPM), always with the same pa-
rameters – = 0.0759, ÷ = 0.5825, “ = 1.09, and µ = 2.40. These values are
the average of the values for –, ÷, “, and µ taken, as usual, from the bank
of identified values of Table B.2 (see Appendix B). The state of the PPM
used in the control law was estimated from the patient BIS, by means of an
observer, as described in (13), with matrix L as in (54).
Notice that, the BIS signal is measured by an electroencephalogram that
also detects muscle activity. Due to this fact, the measurement values may
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present outliers and high frequency noise, since they may be influenced by
more traumatic surgical procedures and/or by a decrease of the patient’s neu-
romuscular blockade level. Therefore, in clinical practices some variations of
the BIS around the pre-specified reference value is accepted.
Due to clinical constraints associated to the anesthetic procedures adjusted
to the patient and also for safety reasons, the controller was not started at
the beginning of the anesthetic procedure. The time for initialization of the
automatic controller was defined by the anesthetists and is marked with a
red arrow in the following figures. In some moments, we may notice the
existence of a big tracking error in the BIS signal. This was due to the fact
that the e ect of muscle relaxants was decreasing, which led to “false” high
BIS values. In these cases, after the administration of an extra bolus of a
muscle relaxant the BIS values decreased almost immediately.
On the other hand, the lower BIS observed during some periods results from
interruptions of the surgery due to a variety of clinical reasons. When the
surgery procedure is more invasive, the BIS signal increases, so the controller
also increases the administered drug doses. It turns out that the reference
tracking is highly dependent on the invasive level of the surgery procedure.
This relevant issue should be taken into account whenever the performance
of automatic control is evaluated. A similar situation occurs during manual
clinical control of the DoA.
In these two patients a change of the reference value for the BIS was suggested
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by the anesthesiologist due to the overall physiological evaluation of the pa-
tients. As it can be observed, the automatic controller presented an adequate
clinical behavior leading to the desired reference tracking. In patient 1, the
proportion (fl) between the administered drug doses had to be changed, due
to clinical indication (this instant is marked with a red row in the graph of
the drug doses of Fig. 3). This happened because although the BIS signal
was within the recommended value, the anesthesiologist considered that the
patient was probably in pain due to sudden changes in the blood pressure
and in the heart rate. Thus it was necessary to increase the administered
dose of the analgesic remifentanil without changing the BIS value. This fact
was achieved by increasing the proportion between the doses of remifentanil
and propofol, which corresponded to increasing the parameter fl. This change
may be observed by looking at the administered drug doses presented in Fig.
3, where the initial proportion between remifentanil and propofol is clearly
lower than the final one. This situation highlights the controller ability of
allowing di erent combinations of drug doses to obtain the same reference
tracking value, dealing with a variety of clinical problems.
The proposed BIS controller performed in practice as theoretically expected
leading to a good clinical performance under a variety of clinical situations,
patients and surgery characteristics. The positive global assessment of the
anesthesiologists concerning the controller features constitutes a strong en-
couragement to use it regularly in clinical practice.
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Figure 3: Printout of the final report of the clinical case of the patient 1. The dashed blue
row on the top graph corresponds to the desired reference value for the BIS. The top red
arrow marks the initialization of the automatic control. The bottom red arrow marks the
increasing of the proportion between remifentanil and propofol. The NMB value is not
presented, because it was manually controlled.
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Figure 4: Printout of the final report of the clinical case of the patient 2. The dashed blue
row on the top graph corresponds to the desired reference value for the BIS. The top red
arrow marks the initialization of the automatic control. The NMB value is not presented,
because it was manually controlled.
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7. Conclusion
Here, a positive state observer was proposed in order to implement a con-
trol law developed for the administration of propofol and of remifentanil for
tracking a desired BIS level. It was proved and illustrated by simulations
that the controller-observer scheme has a very good performance as the BIS
converges to a value in a neighborhood of the desired BIS level.
This controller-observer scheme was implemented and tested for a set of
patients during surgical procedures. This testing showed that the perfor-
mance of the proposed scheme was in accordance with the theoretical results
presented here. Good clinical results were achieved under a variety of clin-
ical situations, patients and surgery characteristics. Due to its satisfactory
performance the anesthesiologists consider it as a potential candidate for
integration into a personalized drug administration system in general anes-
thesia.
Appendix A. PK/PD Model Description
The e ect concentration of propofol (cp
e
) and of remifentanil (cr
e
) can be mod-
eled by the PK/PD state space model (see Bailey and Haddad [25], Marsh
et al. [21], Minto et al. [22], and Schnider et al. [23] - These corresponding
models are summarized in equation (1) of Ionescu et al. [26]):Y
_]
_[
ẋi = Aixi + Biui
ci
e
=
5
0 0 0 1
6
xi,
(A.1)
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where
i = p, r,
xi =
S
WWWWWWWWU
xi1
xi2
xi3
xi4
T
XXXXXXXXV
,
Ai =
S
WWWWWWWWU
≠k10 ≠ k12 ≠ k13 k21V2/V1 k31V3/V1 0
k12V1/V2 ≠k21 0 0
k13V1/V3 0 ≠k31 0
k
e0 0 0 ≠ke0
T
XXXXXXXXV
,
Bi =
S
WWWWWWWWU
1
V1
0
0
0
T
XXXXXXXXV
(A.2)
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Parameters related with the infusion of propofol.
V1 = 4.27 [l]
V2 = 18.9 ≠ 0.391(age ≠ 53) [l]
V3 = 238 [l]
C1 = 1.89 + 0.0456(weight ≠ 77) ≠ 0.0681(lbm ≠ 59) + 0.0264(height ≠ 177) [l/m]
C2 = 1.29 ≠ 0.024(age ≠ 53) [l/m]
C3 = 0.836 [l/m]
K
e0 = 0.456 [min≠1]
K10 =
C1
V1
[min≠1]
K12 =
C2
V1
[min≠1]
K13 =
C3
V1
[min≠1]
K21 =
C2
V2
[min≠1]
K31 =
C3
V3
[min≠1]
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Parameters related with the infusion of remifentanil.
V1 = 5.1 ≠ 0.0201(age ≠ 40) + 0.072(lbm ≠ 55) [l]
V2 = 9.82 ≠ 0.0811(age ≠ 40) + 0.108(lbm ≠ 55) [l]
V3 = 5.42 [l]
C1 = 2.6 ≠ 0.0162(age ≠ 40) + 0.0191(lbm ≠ 55) [l/m]
C2 = 2.05 ≠ 0.0301(age ≠ 40) [l/m]
C3 = 0.076 ≠ 0.00113(age ≠ 40) [l/m]
K
e0 = 0.595 ≠ 0.007(age ≠ 40) [min≠1]
K10 =
C1
V1
[min≠1]
K12 =
C2
V1
[min≠1]
K13 =
C3
V1
[min≠1]
K21 =
C2
V2
[min≠1]
K31 =
C3
V3
[min≠1]
The lean body mass (lbm) for women and men are computed, respectively,
by the equations
1.07weight ≠ 148weight
2
height2
and 1.1weight ≠ 128weight
2
height2
. (A.3)
Appendix B. Database
This database was courteously provided by Galeno project (http://www2.fc.up.pt/galeno/).
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The parameters presented in Table B.2 were identified in Mendonça et al.
[20].
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Table B.1: Patient features
Gender Age Height (cm) Weight (kg)
Patient 1 F 56 160 88
Patient 2 F 48 158 52
Patient 3 F 51 165 55
Patient 4 F 56 160 65
Patient 5 F 64 146 60
Patient 6 F 59 159 110
Patient 7 F 29 163 59
Patient 8 F 45 155 58
Patient 9 F 51 163 55
Patient 10 F 32 172 56
Patient 11 F 68 160 64
Patient 12 F 50 161 68
Patient 13 F 68 158 113
Patient 14 F 70 161 78
Patient 15 F 73 160 75
Patient 16 F 34 162 57
Patient 17 F 43 155 62
Patient 18 F 66 155 74
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Table B.2: PPM parameters
– ÷ “ µ
Patient 1 0.0667 0.3989 1.7695 2.1502
Patient 2 0.0874 0.0670 0.9365 4.7014
Patient 3 0.0693 0.0482 2.8186 1.1700
Patient 4 0.0590 0.0425 2.7594 1.4077
Patient 5 0.0489 0.1269 1.5627 1.4171
Patient 6 0.0677 0.3373 4.1247 1.1444
Patient 7 0.0737 0.2793 0.7812 0.8986
Patient 8 0.0860 0.0212 0.9780 1.4203
Patient 9 0.0701 0.2837 1.0956 1.2164
Patient 10 0.1041 0.1038 1.2165 1.9085
Patient 11 0.0343 3.5768 1.7097 2.5451
Patient 12 0.0467 0.1254 2.4877 1.4884
Patient 13 0.0687 4.5413 1.0859 2.3951
Patient 14 0.0774 0.0397 1.4038 1.5460
Patient 15 0.0995 0.0377 1.3706 2.0485
Patient 16 0.0929 0.1205 4.5194 1.5565
Patient 17 0.0811 0.1033 2.1978 2.0338
Patient 18 0.1336 0.2307 1.0849 1.2061
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Table B.3: PK/PD model parameters - Hill eq.
ECp50 EC
r
50 “ µ
Patient 1 13.94 0.042 2.0321 4.3266
Patient 2 13.88 0.040 1.0133 4.3845
Patient 3 20 0.028 2.0196 3.3133
Patient 4 20 0.052 1.8930 4.2273
Patient 5 14.85 0.1 1.0702 3.9505
Patient 6 20 0.09 2.6169 4.3774
Patient 7 17.08 0.061 3.7297 4.1494
Patient 8 3.35 0.1 0.9172 1.0000
Patient 9 12.17 0.031 1.8645 3.8367
Patient 10 16.91 0.014 1.4517 3.7978
Patient 11 15.52 0.1 0.9334 4.4496
Patient 12 20 0.1 1.6649 4.2860
Patient 13 5.41 0.035 0.9882 3.8094
Patient 14 7.2 0.037 3.8213 3.2302
Patient 15 12.41 0.016 1.6771 3.4726
Patient 16 20 0.046 3.9302 3.9983
Patient 17 20 0.05 1.6096 4.2064
Patient 18 3.43 0.1 1.5613 4.2411
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